Here, we demonstrate that DYNLT1 inhibition can effectively inhibit the proliferation, clone formation, migration and invasion of ER + and TNBC cells, suggesting that DYNLT1 can be used as a new therapeutic target for multiple subtypes, providing a new research direction for the treatment of breast cancer. Here, ESR1 is linked to breast cancer.